Colombian Government And Abbott In Disagreement Over Price Of HIV MedicineApril 2009 | Industry Trend Analysis
The Colombian government and Abbott Laboratories are still in disagreement over the price of the drugmaker's HIV medicine, Kaletra/Aluvia (lopinavir + ritonavir). Colombia, as a middle-income country, is eligible to purchase the drug at a discounted price of US$1,000 per patient per year. However, Abbott says this price does not apply to the private, for-profit healthcare management organisations, who are the majority purchasers of Kaletra. The private organisations will have to pay the market price of US$3,706 per patient per year.
To read the full article, please choose one of the following options: